This is a single-site, longitudinal, open-label, interventional study for evaluating the
effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C
and human immunodeficiency virus (HIV) and taking antiretroviral therapy for HIV.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore